Purpose: Children and adolescents with cancer experience multiple distressing symptoms during and after chemotherapy treatment. This study aimed at secondary analyzing of reported symptoms experienced by Saudi children and adolescents with cancer over multiple cycles of chemotherapy treatment, identifying the experiencing of similar symptom trajectories.
Introduction
Regardless of cancer cytopathological features, it is well documented that children with cancer experience various upsetting symptoms related to disease process or treatment modality (Rodgers et al, 2013) . Satisfactory relief of these distressing symptoms is an imperative goal for patients, parents and practitioners during treatment for cancer (Miller et al, 2011; Rodgers et al, 2016; Hovén et al, 2017) . Not only are these upsetting symptoms key contributors to decreased perception of quality of life, disability to function and disease-related interference with daily activities, but they may also disturb treatment process and impact treatment efficacy (Arslan et al, 2013; Baggott et al, 2014) . Proper and prompt assessment and management of disease-related or treatment-related symptoms decreases recurrent hospitalization, treatment cost, and patient suffering (Kestler and LoBiondo-Wood, 2012; Rodgers et al, 2016; Erdem & Toruner, 2018.) . Dodd, Miaskowski, and Paul (2001) were the pioneers when they authored the first paper on symptom clusters in cancer patients. In that study, they defined symptom cluster as, "three or more concurrent symptoms that are related to each other but are not required to have the same etiology" (p. 468). Four years later, Kim and colleagues (Kim, McGuire, Tulman, & Barsevick, 2005) revised this definition as follows: "two or more symptoms that are related to each other, occur together, composed of stable groups of symptoms, are independent of other clusters and may reveal specific underlying concepts of symptoms." (p. 278). Recently, (Miaskowski et al., 2017) recommended extra elements for symptom cluster definition, including: symptoms that may share a common outcome, the sequential features, and the patient's symptom experience, along with the phenotypic and molecular mechanisms allied with the categories of symptoms inside the symptom cluster.
To date, abundant published research on symptom clusters patterns in pediatric oncology has focused on the complexity of symptoms experienced by children and affirm the diversity and discrepancy in distress level across treatment phases (Docherty, 2003; Ruland et al, 2009; Kestler and LoBiondo-Wood, 2012; Baggott et al, 2010; Baggott et al, 2014; Rodgers et al, 2016; Erdem & Toruner, 2018) . Despite the growing number of symptom trajectory research, no gold standards exist to determine the most fitting tool that could be used to assess symptom clusters; the optimum approaches used for symptom trajectories abstraction; the optimum symptom dimension(s) to use to generate the trajectory; or the utmost proper time to measure the experience of symptoms (e.g., explicit point during the running of cancer treatment protocols). Due to no existing gold standard; a great amount of variability is noticed in the methodologies used to assess symptom clusters in pediatric oncology patients.
The abundance of cancer literature supports a high occurrence of distressing symptoms during chemotherapy in children with different types of cancer. Such symptoms may include but are not limited to, fatigue, insomnia, pain, mood fluctuation, changes in appetite, nausea and vomiting. Studies have found that the prevalence of fatigue and pain in children treated with chemotherapy decreased over time while nausea persisted to stay the same during the hospitalization period for a group of children 10-17 years of age (Miller et al, 2011; Baggott et al, 2014; Rodgers et al, 2016) . In a Turkish study 54 children and adolescents reported 4 to 5 symptom trajectories in the first three months following diagnosis and proved a wide range of emotional and physical symptoms (Atay et al, 2012) .
A previous longitudinal study (Beijers et al, 2012) indicated that the occurrence of chemotherapy -induced symptoms has been reported to be around 75% in the first seven days after administering chemotherapy to children with cancer, and they are also prone to develop these symptoms more than adults in this period. Yeh et al, (2008) used the Memorial Symptom Assessment Scale 10Y18 (MSAS 10-18) to evaluate symptom trajectories among a hundred and forty-four pediatric patients in Taiwan. Results revealed 5 trajectories during stages of chemotherapy treatment as well as after the end of the therapy. The identified 5 trajectories were: (1) symptoms attributed to respiratory and circulatory system malfunction; (2) symptoms attributed to sensory distress and body image; (3) eating difficulties and body image; (4) fatigue, insomnia, and depression and (5) symptoms attributed to GI irritations and discomfort.
Much of the symptom trajectory published papers have focused on using a variable -centered method, which focuses on associations among variables, such as multiple regression and correlation procedures, or on explorations of mean differences, such as analysis of variance (ANOVA). The variable-centered method though, limits generalization of results to subjects since the information attained by the statistical approaches is variable oriented, rather than being individual oriented (Bergman & Magusson, 1997) .
Knowing how symptoms aggregate in Saudi children with cancer during chemotherapy treatment may provide understandings into consequences or outcomes of this disturbing disease. The current study will add to the body of knowledge of disease-related and treatment-related symptom trajectories in children with cancer in Saudi Arabia. Therefore, this study sought to secondary analyze patient-reported symptoms experienced by Saudi children and adolescents with cancer, over multiple cycles of chemotherapy treatment, identifying the experiencing of similar symptom trajectories.
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Methods
Sample and study procedure
This study was a secondary analysis of data collected from a descriptive, longitudinal study that used a package of self-report surveys to attain data from a convenient sample of 132 Saudi children and adolescents who were 14 to 18 years old, able to read and write Arabic and who could sign consent or give assent to a form between February 2013 and June 2014. The purpose of the parent study which was conducted by the same authors was to describe changes in symptom trajectories of 31 symptoms among Saudi children and adolescents during receiving chemotherapy treatment in four tertiary hospitals in Saudi Arabia.
From the parent study 132 participants were identified as eligible to be recruited in this secondary analysis. 2 subjects were excluded from this secondary analysis because they were treated by concurrent radiotherapy. Thus, the total subjects for this analysis were 130.
The parent study used clinical and demographic data questionnaire as well as valid and reliable Arabic versions of Karnofsky Performance Status Scale (KPS) and the Memorial Symptom Assessment Scale (MSAS10-18). Both scales were introduced to the participants three times; the first time was immediately before the administration of the chemotherapy cycle and the other two times were after one and two weeks of receiving the therapy. Although the parent study was approved by Human Subject Review Board at each study site, the current secondary analysis was not considered a human subject research and thus did not need IRB approval.
Measures
Clinical and Demographic data were collected at baseline and included age, gender, time since diagnosis, medical diagnosis, number of relapses and setting of chemotherapy administration (in-patient or out-patient clinics).
Karnofsky Performance Status (KPS) Scale is commonly used in the literature to appraise functional status in patients with cancer and has well recognized reliability and validity (Karnofsky, 1977) . Subjects appraised their functional status using the KPS scale that fluctuated from 30 (I feel severely disabled and need to be hospitalized) to 100 (I feel normal; I have no complaints or symptoms) (Ando et al., 2001; Schnadig et al., 2008) .
The MSAS 10-18 is a self-report survey intended to evaluate the multidimensional experience of symptoms. Using the MSAS, subjects were asked to specify whether they had experienced each symptom in the previous seven days (i.e., occurrence of symptom). If they had experienced the symptom, subjects were asked to rate its severity of occurrence, frequency of occurrence, and distress. Severity of symptom was appraised using a fourpoint Likert scale (i.e., 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). Distress of symptom was assessed using a five-point Likert scale (i.e. 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). The reliability and validity of the MSAS is well recognized in oncology studies (Portenoy et al., 1994a; Portenoy et al., 1994b) .
Translation of the KPS and the MSAS 10-18 into Arabic was done in the parent study. The parent study strictly followed the model of Brislin et al (1973) and the procedures by Miller (2001) . Pretesting of the Arabic language tools was completed with 7 children and adolescents with cancer; they found the tools easy to complete.
Data analysis
Statistical Package for the Social Sciences (SPSS, 2015), version 23.0, was used for data management and calculating descriptive statistics and frequency distributions for demographics and clinical characteristics. Alpha was set at 0.05 and no adjustments were made.
Cluster analysis was carried out using Stata version 13.0 (Stata Corp, 2013) . The authors carried out Latent Class Profile Analysis (LCPA) using Mplus Version 7 (Muthen & Muthen, 1998 . Estimation was done using robust maximum-likelihood through the ExpectationMaximization (EM) algorithm (Muthen & Shedden, 1999 
Results
Clinical and demographic characteristics
The subjects mean age was 15.5 years, and ranged from 11 to 17.5 years. They were mainly Saudi (130, 100%), male (78, 60%), diagnosed with acute lymphoblastic leukemia (52, 40%) and receiving chemotherapy in the inpatient wards (104, 80%), predominantly having average KPS score of 81.0 (SD=16.2). Most subjects had less than one relapse (100, 76.9%). Table 1 presents the results.
Symptom Clusters Identification
The authors identified related symptoms from the MSAS 10-18, which evaluates the experience of symptoms among subjects for the previous 7 days. Amongst the scale's 31 items, seven symptoms (lack of energy, pain, nausea, vomiting, loss of appetite, feeling sad and worrying) showed increase in their occurrence and severity in the results of the parent study. Five symptoms referred to physical dimension (lack of energy, pain, nausea, vomiting, loss of appetite) and the two remaining symptoms referred to psychological dimension (feeling sad and worrying) were introduced in this secondary analysis as proxies for symptom clusters. 
R I g I n A L C o n T R I b u T I o n / C L I n I C A L I n V E S T I g A T I o n
Through using Latent Class Profile Analysis (LCPA), Table  ( 2) reveals that 4 discrete classes of symptom clustering were recognized (Classes I-VI). In order to simplify naming the resulted subgroups, the authors established numerical cut points to be compared with the latent classes of each symptom scores (mild < 1.5; moderate = 1.5-2.5; severe > 2.5). Latent classes were labeled based on the mean scores for MSAS 10-18 as presented in Table ( 3) and Figure (1). Class I (26.2%) was featured by slight levels of psychological (M = 0.67) and physical symptoms (M = 0.77) and was categorized "minimum distress." While class II (30.8%), named "physical prominent distress," was featured by a modest level of psychological symptoms (M = 1.67) but a severe level of physical symptoms (M = 2.81). Meanwhile, class III (20.0%), named "psychological prominent distress," was featured by a severe level of psychological symptoms (M = 2.615) but a modest level of physical symptoms (M = 1.62). Finally, Class VI (23%), named "maximum distress," was featured by severe levels of both psychological symptoms (M = 4.01) and physical symptoms(M = 3.282).
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Discussion
According to authors' best of knowledge this study is the pioneer to use LCPA model to detect symptom aggregation and distribution among Saudi children and adolescents treated with chemotherapy. According to the study results, classifying patients by classes of symptoms clustering could be more helpful clinically in comparison with addressing distinct symptoms, as it might permit practitioners to elucidate which class could be endangered by improper treatment consequences. It could also be helpful to advance strategies of symptom management for grouped and aggregated symptoms, which might be modified to treat a specific symptom profile.
The results of this study revealed four diverse classes of symptom clusters; subjects who experienced minimum distress (Class I), those who experienced physical prominent distress (Class II), subjects who experienced psychological prominent distress (Class III) and those who experienced maximum distress (Class VI). These findings were supported, somehow, by previously conducted studies (Ekti and Conk, 2008; Jager et al, 2008; Yeh et al , 2008; Yeh et al, 2009; Williams et al, 2014) . Vomiting (M=0.88) was reported as the most distressing symptom in Class I, whereas lack of energy was the most prevalent distressing symptom in Class II (M=3.1). Subjects reported worrying (M=2.68) as the most distressing symptom in Class III of clustering, while lack of energy (M= 4.85) was reported to be the most prevalent in Class VI (Yeh et al , 2008; Yeh et al , 2009; Williams et al, 2014; Rodgers et al, 2016) .
Distressing physical symptoms clustering in children with cancer were acknowledged by the findings of previous studies (Rodgers et al, 2016; Erdem & Toruner, 2018) .
Literature conveyed that physical symptoms should not be measured autonomously from psychological symptoms since both of them occur concurrently in children treated with chemotherapy (Rodgers et al, 2016) . This paper acknowledged previous studies results by using MSAS 10-18, which is considered a valuable method for integrating both psychological and physical -related factors into symptom clustering.
Current study results confirmed that clustering of psychological symptoms was vague regardless of the measurement used. Whereas the pervasive nature of clustering of these symptoms approved previous findings of the high occurrence rates for feeling sad ( Erdem & Toruner, 2018) and worrying (Yeh et al , 2008; Yeh et al , 2009; Williams et al, 2014; Rodgers et al, 2016) in children undergoing cancer chemotherapy treatment. Patterns of clustering of physically distressing symptoms; lack of energy pain, nausea, loss of appetite and vomiting were consistent with earlier studies (Ekti and Conk, 2008; Jager et al, 2008; Yeh et al , 2009; Baggott et al, 2012; Williams et al, 2014; Rodgers et al, 2016) .
Quite a few limitations of this study must be acknowledged; using secondary analysis of data may limit the ability to evaluate other important factors to determine groups of clusters. Another limitation recounts to the restricted number of symptoms being evaluated, which might not signify the multifaceted group of symptoms that children with cancer experience. Particularly, two psychological and five physical symptoms were assessed. Small heterogenous sample size (n=130) might affect assessment of symptom aggregation patterns over time.
In spite of limitations, this study findings validated the practicality of LCPA for determination of symptom clusters that may offer information to lead proper management of cancer patients clinically. Additional research is required to assess all possible predictors of numerous symptoms.
In conclusion, no known study recognized the benefits of interventions targeted toward various symptoms in cancer treatment. Treating one symptom may indirectly impact another symptom in the trajectory. For instance, approaches to improve sleep pattern by enhancing pain management could lead to reducing fatigue.
The main findings of this study may have implications for nursing clinical practice. The results verified the interdependence of all dimensions of symptoms clustering, representing that psychological and physical symptoms are not independent in cancer. Yet, practitioners and patients habitually focus more on recognizing physical, more willingly than psychological symptoms.
Conclusion
Understanding antecedents and patterns of symptom trajectories may help practitioners to improve patients' care more efficiently, permitting for refining patient outcomes and inspiring a reduction in health care costs and utilization. The method converging on symptom trajectories is also possible to produce clinically valuable understandings that might lead to the expansion of innovative symptom management protocols. Practitioners could target explicit upsetting symptoms confined within a trajectory to decrease total symptom profile, which will yield decrease of health care cost, mortality and disease-specific morbidity. Furthermore, serving patients recognize how their symptoms group might encourage improved self-management. Patient and practitioner teaching might emphasize the monitoring of symptom grouping rather than separate symptoms and could boost symptom acknowledgement. Alertness of one symptom can prompt self-assessment for the existence of added symptoms if patients recognize that symptoms happen in clusters; responsiveness of further symptoms may enable sensible self-care and avoid costly hospital readmission for symptom management.
